Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

European Respiratory Journal

Volumn 39, Issue 6, 2012, Pages 1551-

  Girard, Nicolas ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

DNA DETERMINATION; DRUG RESPONSE; EGFR GENE; GENE MUTATION; GENOTYPE; HUMAN; LETTER; LUNG ADENOCARCINOMA; MEDICAL DECISION MAKING; NOMOGRAM; PREDICTION; PRIORITY JOURNAL;

EID: 84861856507     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00042912     Document Type: Letter

References (6)

1. Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012; 39: 366-372.
2. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
3. Jiang B, Liu F, Yang L, et al. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 2011; 39: 1392-1401.
4. Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009; 15: 2076-2084.
5. Lecuona A, Heyns CF. A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol. BJU Int 2011; 108: 204-108.
6. Susman E, Phend C. Nomograms inserted into NCCN prostate cancer guidelines. Oncology Times 2003; 25: 28-31.